Background: As few older women with breast cancer receive adjuvant chemotherapy, we examined the barriers and perceptions of 24 UK NHS multidisciplinary breast cancer teams to offering this treatment to women ≥70 years.
educational support for implementation but should standardise care and improve chemotherapy uptake in this increasing population of older patients. Key words: adjuvant chemotherapy, breast cancer, clinical decision making, elderly women introduction The aging of the population has led to a worldwide increase in the number of cancers diagnosed in older people. In the UK, 33% of all breast cancers are now diagnosed in women aged ≥70 years [1, 2] . In 2010, the UK National Cancer Equality Initiative concluded that older patients experienced inequalities in access to cancer services and treatment; furthermore, they also had worse outcomes, which were improving at a slower rate than those for younger patients [3] .
In the 2005 analysis of the Early Breast Cancer Trialists' Collaborative Group, adjuvant chemotherapy in women aged ≥70 years with early breast cancer was found to reduce the risks of recurrence by 12% and death by 13% [4] . The results were not statistically significant owing to the small number of women aged ≥70 years in the analyses; nonetheless, international guidelines recommend that chemotherapy should be considered in older women with breast cancer who are deemed to be fit enough, and in particular in those with highrisk disease [5, 6] . Despite this, across Europe and USA, numerous studies report low rates of receipt of adjuvant chemotherapy in older women [7, 8] . There is therefore an urgent need to understand more about the reasons underpinning the existing treatment decisions made by specialist breast cancer teams. This issue has become all the more important owing to the under-representation of older patients in clinical trials and the failure of recent randomised trials [9] . The drivers and barriers to offering chemotherapy are probably multi-factorial. Undoubtedly, many older women are likely to have pre-existing co-morbidities that might preclude chemotherapy as an option. Some health care professionals may make decisions that are driven by concerns about treatment side-effects and a lack of efficacy data. Some perceive the putative benefits of treatment of the elderly to be too small and others that the patients themselves will decline chemotherapy treatment. The adjuvant chemotherapy in elderly women with breast cancer (AChEW) study was conducted to describe prospectively the clinical decision making of multidisciplinary breast cancer teams regarding adjuvant chemotherapy in women aged ≥70 years with early breast cancer. This information might then be used to identify where interventions should be targeted to increase chemotherapy uptake and optimise care.
methods study design and patients
A study-specific questionnaire was developed by the research team (the authors) and through feedback from additional clinicians. This two-page questionnaire asked clinicians to provide prospectively details about individual patient characteristics and treatment decisions. For each patient, the following data were recorded: tumour characteristics, treatment setting, performance status and whether the questionnaire was completed after a multidisciplinary meeting (team decision) or after a patient consultation (clinician decision). Where patients were not offered adjuvant or neoadjuvant chemotherapy, clinicians were asked to describe why this decision had been reached. Nine pre-defined options were provided, and there was also the opportunity to provide free-text answers. Where patients were offered chemotherapy, oncologists were asked to provide details of the intended treatment regimen and whether the patient had decided to receive it. Three months later, clinicians were asked to report whether or not the patients offered chemotherapy had actually received the treatment.
study conduct
Eligible patients were women aged ≥70 years with a diagnosis of early breast cancer. Participating centres were asked to complete prospectively one questionnaire per patient either after a multidisciplinary team discussion or after a patient consultation depending on where the clinical decision was finally made. Patients who were offered chemotherapy following a consultation with an oncologist were given a participant information sheet inviting them to take part in an interview with a researcher exploring attitudes and decision making regarding chemotherapy (the results of this sub-study will be reported elsewhere). All centres were asked to collect a minimum of 9 months and maximum of 12 months of data.
The study was approved by Brighton West Research Ethics Committee (10/H1111/4) and by Research and Development departments in participating centres. The study was adopted on to the UK National Cancer Research Network portfolio (study ID 8486).
statistical analysis
Completed questionnaires were sent to the co-ordinating centre: Sussex Health Outcomes, Research and Education in Cancer (SHORE-C), for analysis. Data were entered on to an Access database and 100% quality assurance undertaken. Sample size was determined by the number of patients seen in participating centres. Two analyses were planned: the whole study population, and patients who had undergone surgery and had a high risk of recurrence based on pathological parameters where the issue of adjuvant chemotherapy use is most relevant. Patients with a high risk of recurrence were defined as those with breast cancer, which was oestrogen receptor (ER) negative, HER2 positive or ER positive with grade 3 disease and/or 4+ positive nodes [9] . This mirrored the eligibility criteria for the UK ACTION trial, which planned to investigate the benefits of adjuvant chemotherapy in women aged ≥70 years [9] . The data collected were those available at the time the questionnaire was completed and the treatment decision made. Further information may have subsequently become available (for example receptor status), but because this had not been used to inform the treatment recommendation, this was defined as 'unknown/ missing.' Data was then imported into SPSS. The differences between those who were and were not offered chemotherapy, according to clinical and pathological parameters were compared by chi-square test. Logistic regression analyses (using enter selection method) was employed to identify factors that were associated with chemotherapy offer. Variables included in the final multi-variable logistic regression model were age, high-risk profile, hospital type and performance status. Analysis was done using Statistical software IBM SPSS Statistics 20. All tests were two tailed, and P ≤ 0.05 was considered significant. (14) 248 ( Patients who did not have surgery were older (83.9 versus 77.5 years; P < 0.001) and were more likely to receive treatment in a district general hospital (75% versus 25%; P < 0.001). At the time of treatment recommendation and hence questionnaire completion, information regarding performance status and HER2 status were not available in 33% and 29% of patients, respectively. The characteristics of the 803 eligible patients are shown in Table 1 (column 1) .
patients offered chemotherapy all patients
Of the total study population 116/803 (14%) were offered adjuvant or neoadjuvant chemotherapy. The characteristics of those offered chemotherapy or not are shown in Table 1 (columns 2 and 3). Younger patients and those with a better performance status were more likely to be offered chemotherapy. In patients aged ≥80 years (38% of the study population), only 4 of 307 (1.3%) were offered chemotherapy, all were <85 years. Regarding tumour characteristics, patients were more likely to be offered chemotherapy if their breast cancer was higher grade, higher T or N stage, ER negative or HER2 positive. The proportion of patients where a decision was made not to offer chemotherapy following a multidisciplinary meeting (MDM) discussion was 497 (of 803 whole population) and 158 (of 309 high-risk population). There were no differences between academic (teaching) hospitals and district general hospitals in terms of rates of offering chemotherapy. After excluding those with missing performance status or HER2 status, the final logistic regression model was based on 539 patients. This showed that younger age [odds ratio (OR) 0.75, 95% CI 0.69-0.81, P < 0.001], highrisk of recurrence (OR 12.5, 95% CI 6.7-23.4, P < 0.001) and better performance status (OR 15.7, 95% CI 2.0-124.8, P = 0.009) were significantly associated with chemotherapy offer.
high-risk patients
A secondary analysis was restricted to those patients undergoing surgery and meeting the pre-defined high-risk disease characteristics, where the issue of adjuvant chemotherapy use is most relevant. Of the 683 patients who had surgery, 309 (45%) were defined as at high risk of disease recurrence, and 94 (30%) of those women were offered chemotherapy. The characteristics of those women with highrisk disease according to whether chemotherapy was offered are shown in Table 2 .
reasons for not offering chemotherapy
The reasons why chemotherapy was not offered are shown in Table 3 for the whole study population and those at high risk of recurrence following surgery. Respondents could select as many reasons as were relevant from the list, but if stating more than one reason were asked for the most important reason. The most common reasons for not offering chemotherapy in the whole population were that other treatment was more appropriate (the majority of patients for whom this option was selected were ER positive) or that the perceived benefits were too small. In the high-risk group, co-morbidities and frailty were selected as the dominant reason for not offering chemotherapy in 17% and 10% of patients respectively. The reasons for not offering chemotherapy were examined according to age group, Figure 1 . As age increased, clinicians were more likely to cite co-morbidities, frailty, and impairment of quality of life as reasons not to offer chemotherapy, despite the fact that performance status was not documented in 33% of cases.
The probability of being offered chemotherapy varied according to hospital. For the whole study population, the Table S1 , available at Annals of Oncology online). For those high-risk patients who were not offered chemotherapy, the reason cited was 'perceived benefits too small' in 47% of patients overall. However, in individual sites, the proportion of patients for whom this was cited as a reason not to offer chemotherapy varied between 0% and 100%.
type of chemotherapy proposed and acceptance
The type of chemotherapy offered and acceptance rates are shown in Table 4 . Overall, 116 patients were offered chemotherapy, the majority (93 of 116, 80%) after patient consultation. Anthracycline-based regimens were most frequently recommended. At 3-month follow-up, 66 (57%) of the patients received chemotherapy, representing 8% of the 803 patients. Fifty-three of the 66 patients accepting chemotherapy had a high risk of recurrence (17% of all of those with disease at a high risk of recurrence). Of the 116 patients offered chemotherapy, 58 (50%) agreed to be interviewed by the researchers regarding their attitudes to chemotherapy and their decision-making process. These data will be presented elsewhere.
discussion
This study found that of women aged ≥70 years with early breast cancer, only 14% are offered adjuvant chemotherapy, all aged <85 years. It was notable that recommendations regarding chemotherapy were made in the apparent absence of critical information regarding performance status and HER2 status in up to one-third of patients. Many clinicians stated that the most important reason not to offer chemotherapy was that the perceived benefits were too small: 34% in the whole study population and 27% in those women with disease at high risk of recurrence. Co-morbidities and frailty were relatively infrequently cited as the main reason for not offering chemotherapy; although with increasing age, these two factors were found to dominate treatment decisions. There was however considerable variation across hospital sites as to the (2) 3 (2) Data are numbers (percentage) unless stated otherwise.
a Of which 96% ER positive, 94% HER2 negative (whole study population) and 89% ER positive and 84% HER2 negative (high-risk group). The most important reason was cited in 610 patients of the whole study population, and in 183 of the high-risk patients. The key strengths of this study are that the information on which treatment decisions were based was recorded, and that clinicians were asked to describe prospectively their reasons for not offering chemotherapy. This is the first study to address these issues. There are, however, limitations to the approach used: centres opted to become involved in the study, and as such are likely to over-represent those with a specific interest in management of older women with breast cancer. This may lead to bias and may mean that the rate with which chemotherapy offered to older women is over-estimated. The design of the study also makes it difficult to be certain as to the response rate at each participating centre. Nonetheless, the study includes patients with a broad range of histological tumours, with all age groups well represented and from a variety of health care settings. As a result, the patients described are likely to broadly reflect those seen in UK clinical practice.
Two previous studies from the United States describe adjuvant chemotherapy use in older women with early breast cancer [8, 10] . These studies report chemotherapy use in 10% of 70-74-year olds and 4% of 75-79-year olds [8] and 14% of women aged 70 years, respectively [10] . The AChEW study found similar rates of chemotherapy use: 8% of all patients aged ≥70 years. However, the AChEW study builds upon these results by describing the chemotherapy receipt in the subset of patients with high-risk disease (17%) and by describing on an individual patient basis the reasons for not offering chemotherapy.
The patterns of treatment and reasons given for not offering chemotherapy show considerable variation suggesting that clinicians are interpreting the available data in different ways, and that there is little consensus as to what are the benefits of treatment. The UK National Cancer Research Network ACTION trial planned to address this issue in a randomised trial of adjuvant chemotherapy versus no chemotherapy in women aged ≥70 years with early breast cancer [9] . This study failed to recruit, and the resulting lack of direct clinical trial data is likely to undermine confidence in offering chemotherapy. Many treatment decisions were made in the absence of information about HER2 status and performance status. HER2 is a poor prognostic factor in women with early breast cancer whose prognosis might otherwise be good [11] . The influence of general health and 'biological' as opposed to 'chronological' age is also a key factor when considering the advisability of adjuvant chemotherapy [12] , and performance status is a measure of general health. Therefore, there is a risk that without HER2 and performance status the patient may be wrongly assumed to be at low risk of recurrence, or wrongly assumed to be frail (on the basis of their age alone) and chemotherapy erroneously discounted. The introduction of multidisciplinary care has been demonstrated to improve breast cancer survival and reduce variation in survival between hospitals [13] . In order to ensure that these benefits continue to be realised in older patients, it is essential that members of the team have access to all of the relevant data in order to make informed decisions. This is of critical importance because in 62% of the total study population, a decision was made not to offer chemotherapy after an MDM discussion and therefore before (or in the absence of ) a formal consultation with an oncologist. It may be possible to improve multidisciplinary team (MDT) decision making by including a formal geriatric assessment in the information provided to the MDT.
The chemotherapy regimens offered broadly reflect the limited available clinical trial data. The majority of patients were offered anthracycline-based treatment, for which the greatest evidence base exists [14, 15] . There is increasing evidence to support the use of taxane only regimens in older patients (offered to 10% of patients), with the advantages of less cardiac toxicity and superior efficacy, but at the cost of a higher risk of myelo suppression [16] .
The aging of the population means that, in forthcoming years, clinicians are going to be faced with an increasing number of women aged ≥70 years diagnosed with breast cancer. The median life expectancy of a 70-year-old woman in the UK is 17 years [17] . If the survival of these women when diagnosed with breast cancer is to be improved, then national guidelines should be developed and implemented with the support of an educational programme. These should include criteria for defining high risk of recurrence, the minimal acceptable data on which to make a treatment recommendation, a discussion of the incorporation of objective measures of co-morbidities and guidance regarding chemotherapy regimens and doses. Future research also needs to validate the use of fitness scores as predictors of chemotherapy tolerance [18] and explore the influences of women's' preferences for chemotherapy on the decision-making processes.
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